Table 1. Patients characteristics.
| Variables | N=281 | % |
|---|---|---|
| Sex | ||
| Male/female | 161/120 | 57.3/42.7 |
| Age | ||
| Mean ± SD | 65.3±9.58 | – |
| Smoking history | ||
| Present/absent | 163/118 | 58.0/42.0 |
| Histology | ||
| AD/SQ/others | 239/16/26 | 85.1/5.7/9.2 |
| Induction therapy | ||
| Present | 7 | 2.5 |
| pStage | ||
| I/II–III | 108/173 | 38.4/61.6 |
| Surgical procedure | ||
| Standard/limited | 259/22 | 92.2/7.8 |
| Oncogenic status | ||
| EGFR | 135 | 48.0 |
| ALK | 13 | 4.7 |
| KRAS | 33 | 11.7 |
| TN | 100 | 35.6 |
| Adjuvant therapy | ||
| Present | 132 | 47.0 |
| Single organ metastasis | ||
| Present | 167 | 59.4 |
| Treatment for recurrence | ||
| None | 39 | 13.8 |
| RT/S | 37 | 13.2 |
| CT/TKI | 150 | 53.4 |
| RT/S + CT/TKI | 55 | 19.6 |
| TTR (months) | ||
| Mean ± SD | 12.7±8.83 | – |
AD, adenocarcinoma; SQ, squamous cell carcinoma; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog; TN, triple negative; RT/S, radiotherapy and/or surgery; CT/TKI, chemotherapy and/or tyrosine kinase inhibitor treatment; TTR, time to recurrence.